Ian Mortimer, PRESIDENT & CEO at Xenon Pharmaceuticals Inc. (XENE), sold 292,538 shares at $58.81 ($17.6M) on 2026-03-09, disclosed to the SEC on 2026-03-11.
Open-market sale of $17.6M XENE by PRESIDENT & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.81 | 21,791 | $1.3M | 7.3% |
| 2 | $59.26 | 43,348 | $2.6M | 14.6% |
| 3 | $59.50 | 12,479 | $743K | 4.2% |
| 4 | $59.88 | 31,694 | $1.9M | 10.8% |
| 5 | $60.08 | 61,652 | $3.7M | 21.0% |
| 6 | $60.47 | 10,072 |
| $609K |
| 3.5% |
| 7 | $60.49 | 21,515 | $1.3M | 7.4% |
| 8 | $61.26 | 2,449 | $150K | 0.9% |
| 9 | $62.06 | 65,000 | $4.0M | 22.9% |
| 10 | $60.11 | 11,269 | $677K | 3.8% |
| 11 | $60.11 | 11,269 | $677K | 3.8% |
| Total | $60.31 avg | 292,538 | $17.6M | 100% |
| Filing → |
| XENE | SELL | 2026-01-02 | $1.8M | — | Filing → |
| XENE | SELL | 2025-12-09 | $2.3M | — | Filing → |
| XENE | SELL | 2025-12-03 | $4K | — | Filing → |